We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Zinc Absorption From Zinc Citrate, Zinc Gluconate and Zinc Oxide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01576627
Recruitment Status : Completed
First Posted : April 12, 2012
Last Update Posted : January 4, 2013
University of Zurich
Information provided by (Responsible Party):
Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology

Brief Summary:
The goal of this trial is to evaluate zinc citrate, a zinc compound with promising sensory properties and a high zinc content, as an alternative zinc compound to be used for supplementation or food fortification. The bioavailability of zinc citrate given as a supplement to young Swiss adults will be assessed and compared to the bioavailability of the commonly used zinc compounds zinc gluconate and zinc oxide.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: zinc citrate Dietary Supplement: Zinc Gluconate Dietary Supplement: Zinc oxide Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Zinc Absorption From Zinc Supplements Comparing Zinc Citrate to Zinc Gluconate and Zinc Oxide in Young Adults
Study Start Date : March 2012
Actual Primary Completion Date : May 2012
Actual Study Completion Date : November 2012

Arm Intervention/treatment
Experimental: zinc citrate Dietary Supplement: zinc citrate
10 mg of zinc as either zinc citrate

Active Comparator: zinc gluconate Dietary Supplement: Zinc Gluconate
10 mg of zinc as either zinc gluconate

Active Comparator: zinc oxide Dietary Supplement: Zinc oxide
10 mg of zinc as either zinc oxide

Primary Outcome Measures :
  1. Fractional absorption of zinc [ Time Frame: 61 days ]
    Fractional absorption of zinc is estimated by using the double isotope tracer ratio technique by administering 67Zn as oral and 70Zn as intravenous stable isotopes.The urinary enrichment with both isotopes is measured in a spot urine sample by inductively coupled plasma mass spectrometry.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female of 18 to 45 years old
  • Body Mass Index in the range of 19 to 25
  • No mineral and vitamin supplements two weeks prior to the study and during the whole duration of the study

Exclusion Criteria:

  • Any metabolic, gastrointestinal or chronic disease (according to the subjects own statement)
  • Long-term medication during the whole study (except for contraceptives)
  • Vegans
  • Pregnancy
  • Lactation
  • Intention to become pregnant during the course of the study
  • Lack of safe contraception
  • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st test supplement administration
  • Earlier participation in any nutrition study using Zn stable isotopes as well as participation in any other clinical study within the last 30 days and during this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01576627

Layout table for location information
ETH Zurich
Zurich, Switzerland, 8092
Sponsors and Collaborators
Prof. Michael B. Zimmermann
University of Zurich
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof. Michael B. Zimmermann, Prof, Swiss Federal Institute of Technology
ClinicalTrials.gov Identifier: NCT01576627    
Other Study ID Numbers: HNL/CTC11-12
First Posted: April 12, 2012    Key Record Dates
Last Update Posted: January 4, 2013
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Zinc Oxide
Trace Elements
Physiological Effects of Drugs
Dermatologic Agents
Sunscreening Agents
Radiation-Protective Agents
Protective Agents